A BUDGET IMPACT (BI) ANALYSIS OF VACCINATING THE ELDERLY AND AT-RISK ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO NO VACCINATION (NOVAC) OR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN THE UK

被引：1

作者：

Jiang, Y. ^{[1
]}

Gauthier, A. ^{[1
]}

Keeping, S. T. ^{[2
]}

Carroll, S. M. ^{[2
]}

机构：

[1] Amaris, London, England

[2] Sanofi Pasteur MSD, Maidenhead, Berks, England

来源：

VALUE IN HEALTH | 2012年 / 15卷 / 07期

关键词：

D O I：

10.1016/j.jval.2012.08.1086

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A388 / A388

页数：1

共 50 条

[1] MODELLING BUDGET IMPACT (BI) OF VACCINATING AT-RISK ADULTS AND THE ELDERLY WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN GERMANY
Jiang, Y.
Gauthier, A.
Annemans, L.
van der Linden, M.
Nicolas-Spony, L.
Bresse, X.
[J]. VALUE IN HEALTH, 2011, 14 (07) : A268 - A268
[2] ASSESSING THE COST-EFFECTIVENESS (CE) OF VACCINATING THE ELDERLY AND AT-RISK ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) OR NO VACCINATION (NOVAC) IN THE UK
Jiang, Y.
Gauthier, A.
Keeping, S. T.
Carroll, S. M.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A396 - A397
[3] A COST-EFFECTIVENESS ANALYSIS OF VACCINATING THE ELDERLY WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO NO VACCINATION, THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13), OR PCV13 FOLLOWED BY PPV23 IN BRAZIL
Jiang, Y.
Yang, X.
Petigara, T.
Chabrol Haas, L.
Graham, J.
[J]. VALUE IN HEALTH, 2017, 20 (09) : A930 - A930
[4] A cost-effectiveness analysis of vaccinating older adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) compared to no vaccination, the 13-valent pneumococcal conjugate vaccine (PCV13), or PCV13 followed by PPV23 in Colombia
Prieto, E.
Jiang, Y.
Yang, X.
Graham, J. B.
Monsanto, H.
Ruiz, J.
Beltran, C.
Rojas, M.
[J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 13 - 13
[5] THE COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN TAIWAN
Wu, D. B. C.
Chang, C. J.
Chien, L.
Fang, H. C. H.
Roberts, C. S.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A602 - A602
[6] A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
Jiang, Yiling
Gauthier, Aline
Keeping, Sam
Carroll, Stuart
[J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 901 - 911
[7] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
Jiang, Yiling
Gauthier, Aline
Keeping, Sam
Carroll, Stuart
[J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927
[8] COST-EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT CONJUGATE (PCV13) AND 23-VALENT (PPV23) POLYSACCHARIDE PNEUMOCOCCAL VACCINES FOR ADULTS IN SWEDEN
Dorange, A.
Nyman, L.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A216 - A217
[9] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
Shiramoto, Masanari
Hanada, Ryuzo
Juergens, Christine
Shoji, Yasuko
Yoshida, Mizuki
Ballan, Barry
Cooper, David
Gruber, William C.
Scott, Daniel A.
Schmoele-Thoma, Beate
[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (09) : 2198 - 2206
[10] COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPV23) PNEUMOCOCCAL VACCINES FOR SENIOR ADULTS IN BRAZIL
Fujii, R. K.
Mould, J. F.
Presa, J.
Jardim, E.
Sato, R.
Strutton, D. R.
[J]. VALUE IN HEALTH, 2011, 14 (07) : A279 - A279

← 1 2 3 4 5 →